About microphoton x

microphotonX utilizes a photonic single-cell platform that combines Raman Spectroscopy and Optical Tweezers to provide antibiotic susceptibility testing results in 30 to 60 minutes. This technology addresses the urgent need for rapid identification and treatment of multidrug-resistant bacterial infections, significantly reducing the time required for actionable clinical decisions.

```xml <problem> Current antibiotic susceptibility testing (AST) methods can take days to produce actionable results, delaying appropriate treatment and contributing to the spread of multidrug-resistant bacteria. The slow turnaround time hinders effective clinical decision-making, especially in cases of severe infection where rapid intervention is critical. </problem> <solution> microphotonX offers a photonic single-cell analysis platform that delivers antibiotic susceptibility testing (AST) results in 30-60 minutes. The system combines Raman Spectroscopy and Optical Tweezers to analyze individual bacterial cells and detect susceptibility even before cell growth is affected. By identifying cellular reprogramming through chemical analysis, the platform provides physicians with rapid, actionable information for optimal treatment selection. The technology enables detection of polymicrobial infections and simultaneous bacterial identification directly from primary samples. </solution> <features> - Photonic single-cell platform combining Raman Spectroscopy and Optical Tweezers - Rapid AST results in 30-60 minutes - Detects susceptibility before cell growth is affected by identifying cellular reprogramming - Enables detection of polymicrobial infections - Simultaneous bacterial identification - Analysis directly from primary samples - Biospex Analyser 3.0 instrument with automated workflow - AI-aided analysis platform </features> <target_audience> The primary target audience includes physicians and clinical researchers focused on infectious diseases, particularly those needing rapid and accurate AST results to combat multidrug-resistant bacteria. </target_audience> ```

What does microphoton x do?

Where is microphoton x located?

microphoton x is based in Tutzing, Germany.

When was microphoton x founded?

microphoton x was founded in 2021.

How much funding has microphoton x raised?

microphoton x has raised 625800.

Location

Tutzing, Germany

Founded

2021

Funding

625800

Employees

3 employees

Major Investors

Bayern Innovativ Project

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

microphoton x

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

microphotonx.com 1K+

Crunchbase

Founded 2021 – Tutzing, Germany

Funding

Estimated Funding

$500K+

Major Investors

Bayern Innovativ Project

Team (<5)

No team information available.

Company Description

Problem

Current antibiotic susceptibility testing (AST) methods can take days to produce actionable results, delaying appropriate treatment and contributing to the spread of multidrug-resistant bacteria. The slow turnaround time hinders effective clinical decision-making, especially in cases of severe infection where rapid intervention is critical.

Solution

microphotonX offers a photonic single-cell analysis platform that delivers antibiotic susceptibility testing (AST) results in 30-60 minutes. The system combines Raman Spectroscopy and Optical Tweezers to analyze individual bacterial cells and detect susceptibility even before cell growth is affected. By identifying cellular reprogramming through chemical analysis, the platform provides physicians with rapid, actionable information for optimal treatment selection. The technology enables detection of polymicrobial infections and simultaneous bacterial identification directly from primary samples.

Features

Photonic single-cell platform combining Raman Spectroscopy and Optical Tweezers

Rapid AST results in 30-60 minutes

Detects susceptibility before cell growth is affected by identifying cellular reprogramming

Enables detection of polymicrobial infections

Simultaneous bacterial identification

Analysis directly from primary samples

Biospex Analyser 3.0 instrument with automated workflow

AI-aided analysis platform

Target Audience

The primary target audience includes physicians and clinical researchers focused on infectious diseases, particularly those needing rapid and accurate AST results to combat multidrug-resistant bacteria.